Cargando…

Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021)

BACKGROUND: The coronavirus disease 2019 (COVID‐19) has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J‐SSCG) 2020 Special Committee created the Japanese rapid/living recommendat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamakawa, Kazuma, Yamamoto, Ryo, Terayama, Takero, Hashimoto, Hideki, Ishihara, Tadashi, Ishimaru, Go, Imura, Haruki, Okano, Hiromu, Narita, Chihiro, Mayumi, Takuya, Yasuda, Hideto, Yamada, Kohei, Yamada, Hiroyuki, Kawasaki, Tatsuya, Shime, Nobuaki, Doi, Kent, Egi, Moritoki, Ogura, Hiroshi, Aihara, Morio, Kushimoto, Shigeki, Nishida, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594767/
https://www.ncbi.nlm.nih.gov/pubmed/34815889
http://dx.doi.org/10.1002/ams2.706
_version_ 1784600050776670208
author Yamakawa, Kazuma
Yamamoto, Ryo
Terayama, Takero
Hashimoto, Hideki
Ishihara, Tadashi
Ishimaru, Go
Imura, Haruki
Okano, Hiromu
Narita, Chihiro
Mayumi, Takuya
Yasuda, Hideto
Yamada, Kohei
Yamada, Hiroyuki
Kawasaki, Tatsuya
Shime, Nobuaki
Doi, Kent
Egi, Moritoki
Ogura, Hiroshi
Aihara, Morio
Kushimoto, Shigeki
Nishida, Osamu
author_facet Yamakawa, Kazuma
Yamamoto, Ryo
Terayama, Takero
Hashimoto, Hideki
Ishihara, Tadashi
Ishimaru, Go
Imura, Haruki
Okano, Hiromu
Narita, Chihiro
Mayumi, Takuya
Yasuda, Hideto
Yamada, Kohei
Yamada, Hiroyuki
Kawasaki, Tatsuya
Shime, Nobuaki
Doi, Kent
Egi, Moritoki
Ogura, Hiroshi
Aihara, Morio
Kushimoto, Shigeki
Nishida, Osamu
author_sort Yamakawa, Kazuma
collection PubMed
description BACKGROUND: The coronavirus disease 2019 (COVID‐19) has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J‐SSCG) 2020 Special Committee created the Japanese rapid/living recommendations on drug management for COVID‐19 using the experience of creating the J‐SSCG. METHODS: The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to determine the certainty of the evidence and strength of the recommendations. The first edition of this guideline was released on September 9, 2020, and this document is the revised edition (version 4.0; released on September 9, 2021). Clinical questions (CQs) were set for the following seven drugs: favipiravir (CQ1), remdesivir (CQ2), corticosteroids (CQ4), tocilizumab (CQ5), anticoagulants (CQ7), baricitinib (CQ8), and casirivimab/imdevimab (CQ9). Two CQs (hydroxychloroquine [CQ3] and ciclesonide [CQ6]) were retrieved in this updated version. RECOMMENDATIONS: Favipiravir is not suggested for all patients with COVID‐19 (GRADE 2C). Remdesivir is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2B). Corticosteroids are recommended for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 1B) and for patients with severe COVID‐19 requiring mechanical ventilation/intensive care (GRADE 1A); however, their administration is not recommended for patients with mild COVID‐19 not requiring supplemental oxygen (GRADE 1B). Tocilizumab is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2B). Anticoagulant administration is recommended for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization and patients with severe COVID‐19 requiring mechanical ventilation/intensive care (good practice statement). Baricitinib is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2C). Casirivimab/imdevimab is recommended for patients with mild COVID‐19 not requiring supplemental oxygen (GRADE 1B). We hope that these updated clinical practice guidelines will help medical professionals involved in the care of patients with COVID‐19.
format Online
Article
Text
id pubmed-8594767
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85947672021-11-22 Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021) Yamakawa, Kazuma Yamamoto, Ryo Terayama, Takero Hashimoto, Hideki Ishihara, Tadashi Ishimaru, Go Imura, Haruki Okano, Hiromu Narita, Chihiro Mayumi, Takuya Yasuda, Hideto Yamada, Kohei Yamada, Hiroyuki Kawasaki, Tatsuya Shime, Nobuaki Doi, Kent Egi, Moritoki Ogura, Hiroshi Aihara, Morio Kushimoto, Shigeki Nishida, Osamu Acute Med Surg Guidelines BACKGROUND: The coronavirus disease 2019 (COVID‐19) has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J‐SSCG) 2020 Special Committee created the Japanese rapid/living recommendations on drug management for COVID‐19 using the experience of creating the J‐SSCG. METHODS: The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to determine the certainty of the evidence and strength of the recommendations. The first edition of this guideline was released on September 9, 2020, and this document is the revised edition (version 4.0; released on September 9, 2021). Clinical questions (CQs) were set for the following seven drugs: favipiravir (CQ1), remdesivir (CQ2), corticosteroids (CQ4), tocilizumab (CQ5), anticoagulants (CQ7), baricitinib (CQ8), and casirivimab/imdevimab (CQ9). Two CQs (hydroxychloroquine [CQ3] and ciclesonide [CQ6]) were retrieved in this updated version. RECOMMENDATIONS: Favipiravir is not suggested for all patients with COVID‐19 (GRADE 2C). Remdesivir is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2B). Corticosteroids are recommended for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 1B) and for patients with severe COVID‐19 requiring mechanical ventilation/intensive care (GRADE 1A); however, their administration is not recommended for patients with mild COVID‐19 not requiring supplemental oxygen (GRADE 1B). Tocilizumab is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2B). Anticoagulant administration is recommended for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization and patients with severe COVID‐19 requiring mechanical ventilation/intensive care (good practice statement). Baricitinib is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2C). Casirivimab/imdevimab is recommended for patients with mild COVID‐19 not requiring supplemental oxygen (GRADE 1B). We hope that these updated clinical practice guidelines will help medical professionals involved in the care of patients with COVID‐19. John Wiley and Sons Inc. 2021-11-16 /pmc/articles/PMC8594767/ /pubmed/34815889 http://dx.doi.org/10.1002/ams2.706 Text en © 2021 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Guidelines
Yamakawa, Kazuma
Yamamoto, Ryo
Terayama, Takero
Hashimoto, Hideki
Ishihara, Tadashi
Ishimaru, Go
Imura, Haruki
Okano, Hiromu
Narita, Chihiro
Mayumi, Takuya
Yasuda, Hideto
Yamada, Kohei
Yamada, Hiroyuki
Kawasaki, Tatsuya
Shime, Nobuaki
Doi, Kent
Egi, Moritoki
Ogura, Hiroshi
Aihara, Morio
Kushimoto, Shigeki
Nishida, Osamu
Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021)
title Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021)
title_full Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021)
title_fullStr Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021)
title_full_unstemmed Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021)
title_short Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021)
title_sort japanese rapid/living recommendations on drug management for covid‐19: updated guidelines (september 2021)
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594767/
https://www.ncbi.nlm.nih.gov/pubmed/34815889
http://dx.doi.org/10.1002/ams2.706
work_keys_str_mv AT yamakawakazuma japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT yamamotoryo japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT terayamatakero japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT hashimotohideki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT ishiharatadashi japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT ishimarugo japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT imuraharuki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT okanohiromu japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT naritachihiro japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT mayumitakuya japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT yasudahideto japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT yamadakohei japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT yamadahiroyuki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT kawasakitatsuya japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT shimenobuaki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT doikent japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT egimoritoki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT ogurahiroshi japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT aiharamorio japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT kushimotoshigeki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT nishidaosamu japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021
AT japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021